Coral Drugs is an API manufacturer based in India. It holds 30 active US drug master files across a filed portfolio of 10 molecules. Its GMP standing is certified by EMA. Its most recent recorded inspection, by US FDA, closed on 11 December 2019 as VAI. Customs aggregates show $10.0M of exports covering 236 molecules to 38 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| India, India | 3003496619 |
| Sonipat, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Mometasone Furoate | US FDA | 6 |
| Budesonide | SFDA (Saudi Arabia), US FDA | 4 |
| Fluticasone Furoate | US FDA | 4 |
| Fluticasone Propionate | US FDA | 4 |
| Triamcinolone | US FDA | 4 |
| Azelastine | US FDA | 2 |
| Ciclesonide | US FDA | 2 |
| Deflazacort | US FDA | 2 |
| Exemestane | US FDA | 2 |
| Formoterol | US FDA | 2 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| EMA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $1.5M | 18 |
| 2025 | Not reported | $10.0M | 38 |
| 2024 | Not reported | $8.2M | 34 |
| 2023 | Not reported | $7.9M | 26 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Coral Drugs comes back tiered against every other supplier able to file there.
Start for free